



## British Neuro-Oncology Society

*Tel: 07974 436202*

*Fax: 0114 226 8795*

*E-mail: [president@bnos.org.uk](mailto:president@bnos.org.uk)*

*25<sup>th</sup> January 2010*

### **BRITISH NEURO-ONCOLOGY SOCIETY PRESIDENT'S LETTER**

Dear Colleague

It is a privilege and also, of course, a challenge to follow in the footsteps of David Thomas and John Darling as president of the British Neuro-oncology Society, particularly at this time of great change. Over the past few months Council has been working on a number of initiatives to bring BNOS to the forefront of Neuro-oncology clinical care and research in the UK.

Examples of this activity are included in the first of our society newsletters, which is included with this President's letter. These regular publications featuring updates on BNOS activity and news from the world of neuro-oncology will be mailed to BNOS members and posted on the **new** society website.

Featured in this first newsletter are typical examples of BNOS activity in the past few months, together with further information on recent and planned developments in our society.

➤Of course, the jewel in the crown of BNOS activity is our annual scientific meeting, which I believe is world class. This meeting has continued to grow over the past few years and now attracts around 150-200 international speakers and delegates and sets the standards in Neuro-Oncology for the United Kingdom. This year it is Glasgow's turn to host the meeting and we look forward to an excellent programme of speakers and social events.

➤Increasingly, as a representative body for our field, BNOS is invited to comment on matters related to national policy on neuro-oncology care. An example of this is our contribution to the report of the All Parliamentary Party Group enquiry into inequalities in cancer.

➤With the ever increasing membership numbers, website developments and growing correspondence to the society, the task of administering BNOS has grown beyond that which can be achieved in the 'spare' moments between academic and clinical commitments and we are delighted to welcome Ms Jenny Loughlin to the role of Society Administrator.

It should be clear then that the Society is changing; evolving to a more mature, responsive organisation within the world of Neuro-oncology. Nevertheless, it remains the same British Neuro-oncology Society – a society bringing together **all** disciplines allied to neuro-oncology research and clinical practice in the UK.

With that in mind, I look forward to seeing you all in Glasgow in June.

Yours sincerely

**Charles HG Davis FRCS**  
**President British Neuro-oncology Society**